Abstract
We have shown that insulin-like growth factors (IGFs) and their receptor IGF-1R play critical roles in proliferation, survival and drug-resistance of a broad spectrum of hematologic malignancies and solid tumors and that selective inhibitors of IGF-1R kinase activity have in vivo anti-tumor activity in clinically relevant orthotopic tumor models (
Cancer Cell
2004
;5
:221
–30Author notes
Corresponding author
2005, The American Society of Hematology
2004
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal